Literature DB >> 9349420

Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.

C De Smet1, C Lurquin, E De Plaen, F Brasseur, H Zarour, O De Backer, P G Coulie, T Boon.   

Abstract

It is now well established that human melanoma cells express antigens that are recognised by cytolytic T lymphocytes derived from the tumour-bearing patient. The molecular definition of these antigens is progressing at an accelerated pace. The currently characterised melanoma antigens can be classified into three categories: differentiation antigens, antigens encoded by genes that are specifically expressed in tumours, and antigens encoded by mutated genes. Several of these antigens are sufficiently tumour-specific to qualify them as candidate anti-cancer vaccines in melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349420     DOI: 10.1038/eye.1997.59

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

1.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

Review 2.  Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.

Authors:  Natasa Strbo; Arlene Garcia-Soto; Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 3.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

Review 4.  Tumor suppressor maspin as a modulator of host immune response to cancer.

Authors:  Sijana H Dzinic; Maria M Bernardo; Daniel S M Oliveira; Marian Wahba; Wael Sakr; Shijie Sheng
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

Review 5.  Developing recombinant and synthetic vaccines for the treatment of melanoma.

Authors:  N P Restifo; S A Rosenberg
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

Review 6.  Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.

Authors:  Fabricio de Carvalho; André L Vettore; Gisele W B Colleoni
Journal:  Clin Dev Immunol       Date:  2012-03-11

Review 7.  Stromal cells in breast cancer as a potential therapeutic target.

Authors:  Samantha S Dykes; Veronica S Hughes; Jennifer M Wiggins; Henrietta O Fasanya; Mai Tanaka; Dietmar Siemann
Journal:  Oncotarget       Date:  2018-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.